#clinical trials

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

Manusia Pertama yang Mengonsumsi Dasatinib + Quercetin: Apa yang Diperlihatkan (dan Tidak Diperlihatkan) oleh Pilot IPF pada 14 Pasien

BY DR. SYNAPSE · 15 Okt 2026

Pada tahun 2019, peneliti melaporkan penggunaan pertama senolitik kombinasi dasatinib dan quercetin pada 14 pasien fibrosis paru idiopatik. Setelah tiga minggu dosis intermiten, peserta menunjukkan peningkatan jarak tempuh pada tes berjalan 6 menit, kecepatan berjalan, dan waktu bangun dari kursi, meskipun fungsi paru tidak berubah. Studi pilot ini mencatat satu kejadian merugikan serius serta keluhan pernapasan, kulit, dan gastrointestinal yang sering muncul. Namun, ini merupakan studi terbuka tanpa kontrol, menggunakan obat kanker yang dipadukan dengan flavonoid pada dosis farmakologis, bukan protokol suplemen.